Category: Bio & Healthcare

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary ALTEOGEN received official product license approval from the Ministry of Food and Drug Safety (MFDS) for EYZANFY (ALT-L9), an Eylea biosimilar, covering all indications approved for the original drug. 📊 [Key Disclosure Details & Major Figures Summary] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of…

Read More “[Disclosure] ALTEOGEN (196170) – EYZANFY (ALT-L9, Eylea Biosimilar) Approved for Product License by MFDS / 2026-05-15” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Following the exercise of stock options by Celltrion officers and employees, a total of 184,080 new common shares will be issued and additionally listed on May 20, 2026. 📊 [Key Disclosure Details & Financial Summary] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of Total Issued…

Read More “[Disclosure] Celltrion (068270) – Additional Listing (Exercise of Stock Options) / 2026-05-15” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary ALTEOGEN will issue and list 52,500 additional common shares on May 18, 2026, following the exercise of stock options. 📊 [Key Disclosure Details & Major Figures Summary] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of Additional Listing Schedule Execution and Share Count Update This disclosure…

Read More “[Disclosure] ALTEOGEN (196170) – Additional Listing (Exercise of Stock Options) / 2026-05-13” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary The IND amendment filing for Celltrion’s Phase 3 clinical trial of CT-P55 (a Cosentyx biosimilar candidate) in the U.S. was completed as the standard 60-day FDA review period elapsed without separate notification. 📊 [Key Disclosure Details & Financial Summary] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌…

Read More “[Disclosure] Celltrion (068270) – Approval of IND Amendment for CT-P55 (Cosentyx Biosimilar) U.S. Phase 3 Clinical Trial / 2026-05-12” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion has corrected its total acquisition amount to KRW 758.9B following a reduction in the 2nd tranche payment (from USD 86.3M to USD 70.3M) and the finalization of the payment date (May 13, 2026) for its U.S. subsidiary, Celltrion USA, Inc. 📊 [Key Disclosure Details &…

Read More “[Disclosure] Celltrion (068270) – Decision on Acquisition of Other Corporation Shares and Capital Securities (Correction) / 2026-05-11” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion’s 100% subsidiary, Celltrion USA, Inc., has updated its total capital raising amount to USD 516.1M after reducing its second tranche payment (from USD 86.3M to USD 70.3M) and finalizing the payment date for May 13, 2026. 📊 [Key Disclosure Details & Financial Summary] 📝 Editor’s…

Read More “[Disclosure] Celltrion (068270) – Decision on Paid-in Capital Increase by Subsidiary (Correction) / 2026-05-11” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary ALTEOGEN reported provisional consolidated financial results for Q1 2026, recording revenue of KRW 71.60B, operating profit of KRW 39.30B, and net profit of KRW 71.34B. Operating profit increased by 100.1% quarter-on-quarter. 📊 [Key Disclosure Details & Major Figures Summary] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌…

Read More “[Disclosure] ALTEOGEN (196170) – Provisional Consolidated Financial Results / 2026-05-08” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion reported provisional Q1 2026 consolidated revenue of KRW 1.14T and operating profit of KRW 321.87B, marking YoY increases of 36.00% and 115.41%, respectively. 📊 [Key Disclosure Details & Financial Summary] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of Final Audited Figures and Detailed Financial…

Read More “[Disclosure] Celltrion (068270) – Consolidated Financial Results (Provisional Earnings Release) / 2026-05-06” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion has decided to retire 488,983 common shares of treasury stock (worth approx. KRW 100.0B) acquired through open-market purchases on May 21, 2026, to stabilize share prices and enhance shareholder value. 📊 [Key Disclosure Details & Financial Summary] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification…

Read More “[Disclosure] Celltrion (068270) – Decision on Retirement of Shares / 2026-05-06” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion has finalized its share retirement figures following the completion of its treasury stock buyback, adjusting the total retired common shares to 488,977 and the estimated retirement value to KRW 100.07B based on book value. 📊 [Key Disclosure Details & Financial Summary] 📝 Editor’s Comment (Key…

Read More “[Disclosure] Celltrion (068270) – Decision on Retirement of Shares (Correction) / 2026-05-06” »